Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
The safety profile of FAP-IL2v in combination with cetuximab was acceptable, and pharmacodynamic markers support the proposed mode of action of this combination, but the overall low antitumor activity does not warrant further clinical exploration in HNSCC. [Part C of Study BP29842 (NCT02627274).].
Authors
- Marcelo Raul Bonomi (ORCID: https://orcid.org/0000-0002-9399-3608)
- Carlos Gomez‐Roca (ORCID: https://orcid.org/0000-0002-8043-2529)
- Nassim Sleiman (ORCID: https://orcid.org/0009-0004-5705-0786)
- Aaron R. Hansen (ORCID: https://orcid.org/0000-0002-2363-8707)
- Jérôme Fayette (ORCID: https://orcid.org/0000-0002-8126-7019)
- James Spicer (ORCID: https://orcid.org/0000-0003-3732-8491)
- Nino Keshelava (ORCID: https://orcid.org/0009-0001-0978-3393)
- Jiaxin Niu (ORCID: https://orcid.org/0000-0001-9018-287X)
- Stefan Evers (ORCID: https://orcid.org/0009-0001-3060-9429)
- Neeltje Steeghs (ORCID: https://orcid.org/0000-0003-2989-2279)
- David Dejardin (ORCID: https://orcid.org/0000-0001-8960-5345)
- Meike Schneider
- Hans Prenen (ORCID: https://orcid.org/0000-0001-8802-7352)
- Antoîne Italiano (ORCID: https://orcid.org/0000-0002-8540-5351)
- Christophe Boetsch (ORCID: https://orcid.org/0009-0005-8467-0339)
- Julie E. Bauman (ORCID: https://orcid.org/0000-0002-1398-6636)
- Anton Kraxner (ORCID: https://orcid.org/0009-0003-5831-8054)
- Loïc Verlingue (ORCID: https://orcid.org/0000-0002-5694-4022)
- Jehad Charo (ORCID: https://orcid.org/0000-0002-5409-9160)
- Volker Teichgräber (ORCID: https://orcid.org/0009-0008-0526-6584)
- Debbie Robbrecht (ORCID: https://orcid.org/0000-0003-2490-9991)
- Caroline Ardeshir (ORCID: https://orcid.org/0009-0004-9845-8307)
- Daniela Schmid (ORCID: https://orcid.org/0000-0002-8674-593X)
- Christin Habigt (ORCID: https://orcid.org/0009-0008-5806-7650)
Institutions
- Roche (Switzerland) (CH)
- Guy's Hospital (GB)
- The University of Texas MD Anderson Cancer Center (US)
- University of Arizona (US)
- Université de Bordeaux (FR)
- King's College London (GB)
- George Washington University (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Institut Gustave Roussy (FR)
- Erasmus MC (NL)
- Princess Margaret Cancer Centre (CA)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Roche Pharma AG (Germany) (DE)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Antwerp University Hospital (BE)
- Centre Léon Bérard (FR)
- Oncode Institute (NL)
- Roche (United Kingdom) (GB)
- Institut Claudius Regaud (FR)
- Institut Bergonié (FR)
- Erasmus MC Cancer Institute (NL)
- Banner MD Anderson Cancer Center
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1562
- Citations
- 3
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Amgen
- Pfizer
- AstraZeneca
- F. Hoffmann-La Roche
- Les Laboratories Pierre Fabre
- Astellas Pharma
- European Society for Medical Oncology
- PharmaMar
- Foundation Medicine